ArticleNature2026
NSD2 targeting reverses plasticity and drug resistance in prostate cancer.
RetractedAbstract readRetracted Publication
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Great Escape: the systems biology of endocrine resistance and lineage plasticity.Endocrine-related cancer · 2026Review
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.The Journal of experimental medicine · 2026Article
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- pyVIPER: a fast and scalable Python package for protein activity estimation and master regulator analysis of single-cell RNA sequencing data.BMC bioinformatics · 2026Article
- Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer.Neoplasia (New York, N.Y.) · 2026Article
- Endocrine-driven inflammatory-epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis.Frontiers in endocrinology · 2026Review
- Epigenetic plasticity and chemoresistance in cancer: mechanisms, biomarkers, and translational opportunities for real-world evidence.Frontiers in cell and developmental biology · 2026Review
- Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology.Frontiers in oncology · 2026Review
- Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026Review
- Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer.Frontiers in endocrinology · 2025Review
Corrections and comments
- Retraction · 2026-06-30Concerns/Issues about Animal Welfare · Concerns/Issues about Image · Investigation by Journal/Publisher · Investigation by Third Party · Lack of IRB/IACUC Approval and/or Compliance · Objections by Author(s) · · see also: https://pubpeer.com/publications/D21C51ED8057A920FE185F8D175B70
- Retracted
Authors and funding
29 authors.
Jia J Li *Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0003-3676-5657
Alessandro Vasciaveo *Department of Systems Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0003-0205-9869
Dimitris KaragiannisDepartment of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Zhen SunHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kristjan H GretarssonDepartment of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0002-9616-416X
Xiao ChenDepartment of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Ouathek OuerfelliOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7038-0219
Fabio SocciarelliDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Ziv FrankensteinHerbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Hanyang DongDepartment of Biology, Stanford University, Stanford, CA, USA.
Min ZouHerbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Wei YuanDivision of Clinical Studies, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-8004-1846
Guangli YangOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gabriel M AizenmanCenter for Data Science and Artificial Intelligence, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Tania PannelliniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Xinjing XuDepartment of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0001-6677-711X
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3259-2226
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0171-3884
Kevin GardnerHerbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0001-8018-4353
Brian D RobinsonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0001-5374-890X
Johann de BonoDivision of Clinical Studies, The Institute of Cancer Research, London, UK.
Or GozaniDepartment of Biology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-1365-4463
Cory Abate-ShenDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0002-5021-0570
Mark A RubinDepartment of Biomedical Research, Bern Center for Precision Medicine, University of Bern, Bern, Switzerland.
Massimo LodaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0001-9674-8379
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4955-6475
Andrea CalifanoDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID http://orcid.org/0000-0003-4742-3679
Chao LuDepartment of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. cl3684@cumc.columbia.edu.ORCID http://orcid.org/0000-0003-0982-8122
Michael M ShenDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. mshen@columbia.edu.ORCID http://orcid.org/0000-0002-4042-1657
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MProject 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LODA, MASSIMO · 2017 to 2021
$10.9MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MPreclinical analyses of advanced prostate cancer in genetically-engineered miceR01CA173481 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Cory Abate-Shen · 2013 to 2026
$6.1MPatient-Derived Models of Prostate Cancer for Personalized MedicineU01CA224044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YU, FUTREAL, PHILLIP ANDREW · 2019 to 2023
$5.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MMolecular mechanisms of prostate cancer metastasisR01CA183929 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2025
$4.1MMolecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1MNCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013696NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA173481NCI NIH HHS R01 CA183929NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA208100NCI NIH HHS R01 CA238005NCI NIH HHS R01 CA251527NCI NIH HHS R01 CA253368NCI NIH HHS R01 CA265026NCI NIH HHS R01 CA266040NCI NIH HHS R01 CA272844NCI NIH HHS R35 CA197745NCI NIH HHS R37 CA241486NCI NIH HHS R50 CA243895NCI NIH HHS U01 CA224044NCI NIH HHS U01 CA261822NCI NIH HHS U54 CA224079NIDCR NIH HHS R01 DE031873NIDDK NIH HHS R01 DK132251NIGMS NIH HHS R35 GM138181NIGMS NIH HHS R35 GM139569NIH HHS S10 OD012351NIH HHS S10 OD021764
Abstract
Lineage plasticity is a cancer hallmark that drives disease progression and treatment resistance
Indexed as
Cell PlasticityDrug Resistance, NeoplasmHistone-Lysine N-MethyltransferaseProstatic Neoplasms, Castration-ResistantRepressor ProteinsAdenocarcinomaAnimalsBenzamidesCell Line, TumorCell TransdifferentiationGene Expression Regulation, NeoplasticHistonesHumansMaleMethylationMiceBenzamidesenzalutamideHistone-Lysine N-MethyltransferaseHistonesNitrilesNSD2 protein, humanPhenylthiohydantoinReceptors, AndrogenRepressor Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.